Clinical trials: Moxifloxacin
Multi-drug Resistant Tuberculosis
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and…
- Trial name
- NCT03830671
- Testing
- 18-month regimen containing 6 anti-TB drugs
- Where
- 20 sites in China
- Volunteers
- 515 people
- Sponsor
- Beijing Chest Hospital
Healthy Volunteers
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
The purpose of this study is to evaluate the effect of CC-99677 coadministration on the pharmacokinetics (PK) of an oral contraceptive (OC).
- Trial name
- NCT04718636
- Testing
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Stenotrophomonas Maltophilia Infection
Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia
Multi center, retrospective chart review of patients admitted to MHS hospitals from April 1, 2017 to March 31, 2022. Patients will be identified through the electronic medical record, and data from those that meet the study…
- Trial name
- NCT06112938
- Testing
- Antibiotic
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Methodist Health System
Healthy
A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects
This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects.
- Trial name
- NCT06310876
- Testing
- ABBV-CLS-7262, Moxifloxacin 400mg
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Calico Life Sciences LLC
Healthy
Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers
Study to investigate the effect of BI 1744 CL on the QT/QTc interval of the ECG (electrocardiogram) in comparison to placebo
- Trial name
- NCT02172144
- Testing
- BI 1744 CL solution for inhalation, Moxifloxacin (Avalox®)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers
Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin
- Trial name
- NCT02256735
- Testing
- Treatment A, Treatment B, Treatment C
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Amenorrhea
Study of Leptin for the Treatment of Hypothalamic Amenorrhea
The purpose of this study is to determine whether administration of an investigational medication called leptin (r-metHuLeptin) in replacement doses can improve bone health, reproductive function, hormone levels, immune function…
- Trial name
- NCT00130117
- Testing
- r-metHuLeptin, Oral Contraceptive Pills (OCPs)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Triple Negative Breast Cancer
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.
- Trial name
- NCT04722978
- Testing
- Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Cataracts
VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery
The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%) ophthalmic solution in the prevention of…
- Trial name
- NCT01515826
- Testing
- Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel), Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
- Sponsor
- Alcon Research
Headache, Migraine
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
- Trial name
- NCT02792517
- Testing
- Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
- Where
- 4 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Amgen
Solid Tumors
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
This is a randomized, placebo-controlled, double-blind, 3-way crossover phase I study being conducted on healthy volunteers to investigate the effect of single dose of AZD6094 (600 mg) on cardiac repolarization under…
- Trial name
- NCT03258515
- Testing
- AZD6094 200 mg, Moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
PanACEA - STEP2C -01
This is a phase 2B/C, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.
- Trial name
- NCT05807399
- Testing
- BTZ-043, Rifampicin, Isoniazid
- Where
- 10 sites in Gabon, Malawi and 4 more
- Volunteers
- 390 people
- Sponsor
- Michael Hoelscher
Tuberculosis
Asymptomatic TB With Innovative Modified Short-course Regimens
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of…
- Trial name
- SWIFT (NCT06153069)
- Testing
- Four-month regimen, Three-month regimen, Standard regimen
- Where
- 5 sites in China
- Volunteers
- 426 people
- Sponsor
- Huashan Hospital
Pediatric ALL
Pharmacokinetics of Drugs Administered to Children
This is a prospective study of children <21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver.
- Trial name
- NCT03481881
- Testing
- Standard of care drug
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Duke University
Multidrug Resistant Tuberculosis
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to pyrazinamide) treatments for 24 to 32 weeks…
- Trial name
- TB-TRUST (NCT03867136)
- Testing
- PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen
- Where
- 13 sites in China
- Volunteers
- 354 people
- Sponsor
- Huashan Hospital
Healthy Subjects
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects
The primary objective is to evaluate the cardiac safety of a single oral dose (400 mg) of pacritinib compared to placebo on the QT calculated using the Fridericia correction (QTcF) interval in healthy subjects.
- Trial name
- NCT02807207
- Testing
- A: pacritinib, C: moxifloxacin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Multidrug Resistant Tuberculosis
NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
Tuberculosis (TB) has been one of the top 10 causes of death worldwide from a single infectious agent, ranking above HIV/AIDS. Management and eradication of this disease is being hindered by the emergence of multidrug-resistant…
- Trial name
- GRACE-TB (NCT03604848)
- Testing
- WHO-approved MDR-TB regimen, NGS-guided regimen: Regimen A, NGS-guided regimen: Regimen B
- Where
- 12 sites in China
- Volunteers
- 488 people
- Sponsor
- Huashan Hospital
Healthy
Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart
To evaluate whether Rodatristat Ethyl prolongs the QTc interval when orally administered to healthy volunteers.
- Trial name
- NCT05933447
- Testing
- Rodatristat Ethyl, Moxifloxacin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Altavant Sciences GmbH
Healthy Participants
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF)…
- Trial name
- NCT06194032
- Testing
- Baxdrostat, Moxifloxacin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca